Avenda Health Raises $10M in Series B

Innovating Detection and Treatment for Prostate Cancer Care

Avenda Health, an AI healthcare company creating the future of personalized prostate cancer care, today announced it has raised $10M in Series B funding led by VCapital. The round also includes participation from Plug & Play Ventures and Wealthing VC Club.

Avenda Health notes the capital will be used to accelerate the use of iQuest, an AI-enabled patient management software that identifies and visualizes a patient’s prostate cancer. The funding will also be used to continue clinical evidence development.

Avenda Health has introduced technology that is innovating the men’s health industry to improve treatment and cancer mapping for prostate cancer care. The Avenda Health FocalPoint System powered by iQuest reimagines laser ablation with a system to treat prostate cancer in-office under ultrasound guidance while preserving quality of life. The system spares healthy tissue by targeting only the tumor, which minimizes side effects, and uses patient-specific information and AI to deliver a precise and personalized treatment. To better predict the extent of disease and support decision-making in cancer care, Avenda Health developed iQuest, which uses AI-deep learning to uncover cancer previously hidden within traditional MRI mapping and can be used by physicians to better plan treatments.

“Our company’s mission is to provide clinicians and their patients greater access to care while maintaining quality of life that is often missing in prostate cancer treatment. Our technology is solving key issues in men’s health and we look forward to creating real change in prostate cancer care,” said Dr. Shyam Natarajan, co-founder and CEO of Avenda Health. “This funding will play a critical role in expanding the capability and reach of our technology, while adding to our experienced team of Urology, medical device, and AI leaders.”

At the 2022 American Urological Association annual meeting, a retrospective study of 50 patients showed iQuest improved tumor encapsulation1 over conventional treatment planning from 56 percent to 80 percent2. In 2021, the company received Breakthrough Device Designation FDA clearance for the Avenda Health Focal Therapy System. The system was also voted the “Most Promising Ablative Technology” at FOCAL 2020: Focal Therapy Gauntlet, attended by top urologists from around the country.

“We are thrilled to be a part of Avenda Health’s journey in making incredible strides in the future of prostate cancer care, ” said Ryan Kole, Partner at VCapital. “Investing in something meaningful, innovative and groundbreaking in men’s health, is something VCapital is proud of.”

FocalPoint is FDA cleared for soft tissue ablation. iQuest and its use with FocalPoint are not FDA cleared and are for investigational use only.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides our readership with breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

MMI notes the funds will support commercialization of the Symani® Surgical System in high-growth markets and continued investment in studies that generate clinical evidence and enable indication expansion. Investments will also accelerate advanced technology capabilities and enable MMI to scale its operational capabilities globally.
“We are excited to begin our journey as a public company with this additional investment. We believe Tevogen’s patient-centric approach, which merges a focus on affordability with advanced science, is a blueprint for sustainable success in the current era of healthcare. I am pleased that investors now have the opportunity to participate in Tevogen’s mission to become the very first life science company offering commercially attractive and affordable personalized T cell therapies for large patient populations in virology, oncology, and neurology, said the CEO of Tevogen Bio.
MB2 Dental notes the financing will be used to fund upcoming acquisitions and future growth for the company, following a record year of growth in 2023 with 150 new partnerships.
Procyrion notes the funding will support the DRAIN-HF pivotal IDE trial evaluating the company's Aortix pump, internal R&D programs to improve manufacturability, and commercialization preparation.
PhotoniCare, in January of this year, announced that the U.S. Food and Drug Administration had granted clearance for its TOMi™ Scope for non-invasive imaging of the middle ear.

By using this website you agree to accept Medical Device News Magazine Privacy Policy